Acasti Pharma Stock Price

0.0019 (0.36%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Acasti Pharma Inc ACST NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0019 0.36% 0.53 19:58:41
Open Price Low Price High Price Close Price Prev Close
0.5366 0.52 0.558 0.5255 0.5281
Bid Price Ask Price Spread News
0.53 0.538 0.008 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
5,888 4,606,132 $ 0.5358703 $ 2,468,289 15,354,547 0.171 - 1.22
Last Trade Time Type Quantity Stock Price Currency
19:58:41 formt 1,775 $ 0.53 USD

Acasti Pharma Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 51.35M 96.89M 77.93M $ - $ - -0.71 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Acasti Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ACST Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.57190.58810.5110.54639377,072,018-0.0419-7.33%
1 Month0.570.6120.470.532205112,511,446-0.04-7.02%
3 Months0.570.640.3810.506727811,894,277-0.04-7.02%
6 Months0.2631.220.24510.634068232,539,0760.267101.52%
1 Year0.7881.220.1710.588525919,198,100-0.258-32.74%
3 Years0.7093.080.1710.69653437,452,663-0.179-25.25%
5 Years1.523.35650.1710.71513374,585,438-0.99-65.13%

Acasti Pharma Description

Acasti Pharma Inc is a biopharmaceutical innovator advancing a cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company is focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the blood lipids associated with cardiovascular disease risk. The Company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemia.

Your Recent History
Acasti Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.